The Cole Eye Institute Retina Summit took place on Friday, April 27, 2018

This Summit provides a comprehensive medical and surgical update in new advancements in retinal imaging critical to enhance the accuracy of diagnosis and to improve treatment outcomes for diseases of the retina and vitreoretinal interface.

Session Topics

RETINOVASCULAR DISEASES & UVEITIS

Promising Future Therapies in Development for DME – Peter K. Kaiser, MD
Update on DRCR.net Studies – Judy E. Kim, MD
Management of Myopic Choroidal Neovascularization – Rishi P. Singh, MD
Systemic Medications and Retinal Toxicity  – William F. Mieler, MD
What’s New in Local Uveitis Management – Sunil K. Srivastava, MD
PANEL: Treating Retinal Vascular Disease – Moderator: Rishi P. Singh, MD

RETINOVASCULAR DISEASES & UVEITIS

  • Retinovascular Diseases & Uveitis Audio Session

Release Date: June 29, 2018

Expiration Date: June 29, 2019

Target Audience
This activity is for retina specialists, retina fellows and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treating retinal and vitreoretinal diseases.

Learning Objectives
Upon completion of the educational activity, participants should be able to:

  • Assess treatment strategies for retinal diseases
  • Identify therapeutic options for the management of treatment-resistant retinal diseases
  • Employ treatment protocols to optimize outcomes over the long term for patients with retinal disease
  • Integrate imaging technologies into clinical practice for early detection, typing, and monitoring of retinal diseases
  • Adopt best practices in surgery for patients with retinal disease
  • Summarize recent clinical trial data for emerging and established therapies for retinal diseases

Criteria for Success
In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon successful completion of the post test and online evaluation/claim credit form. If you have questions about this CME activity, please contact AKH Inc. at jgoldman@akhcme.com.

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc., Alcon Laboratories, Inc., Genentech, and Santen.

Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Planner Disclosures
Dorothy Caputo, MA, BSN, RN – CE Director of Accreditations
N/A – Nothing to disclose

MCME Global Staff and Planners
N/A – Nothing to disclose

AKH Planners and Reviewers
N/A – Nothing to disclose

Faculty Disclosures

Netan Choudhry, MD, FRCSC, DABO
Medical Director
Vitreous Retina Macula Specialists of Toronto
Etobicoke, ON

Consultant – Bayer, Allergan, Optos, Johnson & Johnson
Speakers Bureau – Topcon, Optos PLC, Allergan, Bayer
Contracted Research – Topcon, Bayer

—————–
Justis Ehlers, MD
The Norman C. and Donna L. Harbert Endowed Chair of Ophthalmic Research
Cleveland Clinic
Cleveland, OH

Consultant – Alcon, Thrombogenics, Santen, Zeiss, Alimera, Leica, Genentech
Contracted Research – Alcon, Genentech, Regeneron

—————–
Allen C. Ho, MD
Consultant – Alcon – Fort Worth, TX – Consulting, grant
Genentech – San Francisco, CA – Consulting, grant; Janssen – Spring House, PA – Consulting, grant; Regeneron – Tarrtown, NJ – Consulting, grant; Regenix – Rockville, MD – Consulting, grant

—————-
Peter K. Kaiser, MD
Staff Physician
Cole Eye Institute
Pepper Pike, OH

Consultant – Alcon, Allergan, Allegro, Aerpio, Bausch and Lomb, Bayer, Benitec, Biogen Idec, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside, Eyevensys, Ocunexus, Omeros, ONL, Regeneron, Novartis, Kanghong, Ophthotech, Ohr, Santen, SciFluor, Shire, Thrombogenics

—————-
Judy E. Kim, MD
Professor of Ophthalmology
Medical College of Wisconsin

Consultant – Genentech, Carl Zeiss, NotalVision, Alimera Sciences

—————–
Gregg T. Kokame, MD, MMM
Clinical Professor
University of Hawaii School of Medicine
Medical Director
Hawaii Marcula and Retina Institute
Managing Partner of Retina Consultants of Hawaii

Speakers Bureau – Regeneron, Bayer, Second Sight, Bausch and Lomb
Consultant – Genentech, Santen, Regeneron, Bayer, Bausch and Lomb, Zeiss, Ophthotech, Allergan
Contracted Research – Genentech, Regeneron

——————-
Daniel F. Martin, MD
Institute Chair
Cole Eye Institute, Cleveland Clinic
Cleveland, OH

N/A – Nothing to disclose

——————-
William F. Mieler, MD
Cless Family Professor of Ophthamology
University of Illinois at Chicago
Chicago, IL

N/A – Nothing to disclose

——————-
Rishi P. Singh, MD
Cole Eye Institute, Cleveland Clinic
Cleveland, OH

Consultant – Genentech, Regeneron, Zeiss, Optos
Contracted Research – Apellis

——————-
Richard F. Spaide, MD
Vitreous Retina Macula Consultants of New York
New York, NY

Consultant – Topcon, Boehringer Ingelheim
Royalty – Topcon Medical Systems, DORC

——————-
Sunil K Srivastava MD
Staff Physician
Cleveland Clinic
Cleveland, OH

Consultant – Santen, Bausch and Lomb, Allergan, Gilead, Regeneron, Psivida
Contracted Research – Santen, Psivida, Bausch and Lomb

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.

Advancing Knowledge in Healthcare    mcme-logo

X

PRE-QUESTIONS

Please answer the following pre-questions before moving on to the seminar presentation.

First Name*
Last Name*
Email*

Approximately how many individuals in the United States are affected by myopic choroidal neovascularization?

41,000
10,500
100,000
55,000

Dave is a 66-year-old male retired IT developer. He reports cloudy vision in his left eye for the last four days, severe photophobia and tearing. He has not had an eye exam in 3 years and reports no prior eye injury or surgeries, and no history of eye trauma. His past medical history is positive for a myocardial infarction and stent placement 3 years ago. His current medications include aspirin, clopidogrel, and lisinopril. On examination, his right distance visual acuity (VA) was 20/150 OD and 20/150 OS. There is a 3+ anterior chamber reaction on the right with associated fine keratic precipitates and significant corneal edema. You diagnose acute anterior uveitis. Which of the following agents may be used as a local treatment for this patient?

Etanercept
Infliximab
Adalimumab
Prednisolone acetate, 1%